Alkem Laboratories Ltd. has announced its standalone and consolidated financial results for the second quarter and first half of FY27, ending September 30, 2026. The company reported a 13.8% YoY growth in total revenue from operations for Q2 FY27, reaching ₹45,520 million. EBITDA grew by 11.3% YoY to ₹10,252 million, with a margin of 22.5%. Net profit declined 11.7% YoY to ₹6,753 million, primarily due to a higher effective tax rate.
Alkem Laboratories Announces Q2 and H1 FY27 Financial Results
Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the second quarter (Q2 FY27) and the first half of the financial year 2027 (H1 FY27), both ended September 30, 2026. The Board of Directors reviewed these results at its meeting held in Mumbai.
Q2 FY27 Key Financial Performance
For the second quarter of FY27, Alkem Laboratories reported a Total Revenue from Operations of ₹45,520 million, marking a 13.8% Year-on-Year (YoY) growth. The EBITDA for the quarter stood at ₹10,252 million, with an EBITDA margin of 22.5%, reflecting an 11.3% YoY growth. Profit Before Tax (PBT) before exceptional items was ₹9,646 million, up 7.7% YoY. However, Net Profit (PAT) for the quarter declined by 11.7% YoY to ₹6,753 million, attributed to a higher effective tax rate. Basic and Diluted Earnings Per Share (EPS) were ₹56.
The company’s India business showed a growth of 9.5% YoY, with sales amounting to ₹30,275 million. International sales grew by 22.3% to ₹14,540 million. Biotech sales experienced a degrowth of 35%, while MedTech sales, including the integrated Occlutech, were ₹1,331 million.
H1 FY27 Performance Highlights
For the first half of FY27, the Total Revenue from Operations was ₹82,921 million, an increase of 12.5% YoY. EBITDA grew by 7.9% YoY to ₹17,912 million. PBT before exceptional items increased by 5.0% YoY to ₹17,366 million. Net Profit (PAT) for H1 FY27 saw a decline of 16.4% YoY to ₹11,953 million, with EPS at 100.
Operational and Business Highlights
Mr. Sandeep Singh, MD of Alkem, commented on the results, highlighting the continued momentum in the Indian business and steady progress in the international markets. The company noted the expansion of its MedTech presence through the addition of Occlutech. Key financial highlights also include R&D expenses of ₹1,953 million for Q2 FY27, representing 4.3% of total revenue. Net cash stood at INR 49,054 million as of September 30, 2026.
The company also provided updates on its domestic business, noting that its contribution to total sales was 68% in Q2 FY26. It registered a growth of 13.8% YoY, at par with the Indian Pharmaceutical Market (IPM). In international markets, Non-US sales grew 58% YoY to INR 6,710 million. The company also detailed its facility regulatory status for its Baddi, Daman, Taloja, Ankleshwar, Mandva, and California facilities.
Source: BSE
